Climate change and global warming resulting from greenhouse gas emissions are widely recognized as the biggest threats to global health. The healthcare sector is responsible for 4–5% of global emissions, more than 70% of which are driven by supply chains.
Cell & Gene Therapy
Viewing related articles
A BioPhorum member only survey to help gain further insight around how the industry is approaching scaling the production of AAV in suspension HEK- 293 cells from lab to commercial scale.
BioPhorum member only benchmarking exercise seeking member experience on expectations for mycoplasma testing of cell therapies.
BioPhorum member benchmarking survey on testing strategies for AAV and LVV empty, full and partially filled capsids.
A BioPhorum member survey examining approaches to testing allogenic cell therapies for adventitious viral contaminants.
A BioPhorum member only survey to understand viral purification and clearance practices member companies are undertaking in CGT.
A BioPhorum member only survey is to gather information to benchmark what analytical controls member companies are currently using to establish methods to test identity, strength, potency and purity.
A BioPhorum member only benchmarking survey to understand the current challenges and strategies undertaking regarding leveraging process characterization data/use of platforms to accelerate validation.
This article and template summarize the main steps in a suggested EHS risk assessment process and can form the basis for discussions between a contract manufacturer and client or between production and development departments.
A BioPhorum member survey aimed to gather initial industry benchmarking data and interest in defining an industry position on visible particulate control strategy for cell and gene therapies.